Ipsen’s mission, “innovate for patient care”, highlights our determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. Our ambition for R&D is based on an intensified partnership policy, a promising pipeline, two technological platforms specializing in peptides and toxins, and three benchmark R&D centers around the world.
2 innovative scientific platforms
Focused on peptides and toxins, our R&D teams are constantly deepening and adding to the expertise of these two platforms. Our goal is to improve understanding of both the basic science and clinical aspects of peptides and toxins. Ipsen has entered into agreements with highly specialized companies in these fields and is strengthening its partnership policy through agreements with major global research institutes and medical centers of excellence.
3 benchmark R&D centers
Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States: to foster open innovation, Ipsen has set up its R&D centers at the heart of three internationally reputed scientific hubs, in close contact with leading academic research centers, cutting-edge medical centers and biotechnology companies.
Ipsen’s Research & Development comprises both new molecule development programs and lifecycle management programs for our existing products. During preclinical and clinical development, early identification of therapeutic targets and markers helps researchers to better define the potential value of molecules. This accelerates the process of drug development and drug approval application procedures.
Ipsen’s Scientific Affairs department manages external public and private collaborations. The partnerships that we develop with major research institutes and medical centers of excellence especially provide the opportunity to test the feasibility of our research concepts.